Funding for this research was provided by:
Text and Data Mining valid from 2018-09-14
Received: 19 March 2018
Accepted: 27 August 2018
First Online: 14 September 2018
Ethics approval and consent to participate
: The study protocol, amendments, and subject informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Informed consent was obtained from subjects and documented in accordance with local regulations, ICH-GCP requirements, and the ethical principles that have their origin in the principles of the Declaration of Helsinki.
: Not applicable.
: RL has received consultancy fees and/or research grants and/or speaker’s bureau from AbbVie, Ablynx, Amgen, AstraZeneca, Bristol-Myers Squibb, Centocor, GlaxoSmithKline, Novartis, Merck, Pfizer, Roche, Schering-Plough, and UCB Pharma. TN is an employee of UCB Pharma. OD is an employee and stockholder of UCB Pharma. DB has acted as an advisor and/or provided research collaboration for AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB Pharma, and is an employee of UCB Pharma.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.